BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16333676)

  • 1. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin.
    Damber JE; Vallbo C; Albertsson P; Lennernäs B; Norrby K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):354-60. PubMed ID: 16333676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.
    Vallbo C; Damber JE
    Acta Oncol; 2005; 44(3):293-8. PubMed ID: 16076702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    Corcoran NM; Costello AJ
    BJU Int; 2005 Sep; 96(4):640-6. PubMed ID: 16104925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study.
    Lennernäs B; Albertsson P; Damber JE; Norrby K
    APMIS; 2004 Mar; 112(3):201-9. PubMed ID: 15153162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2008; 47(2):293-300. PubMed ID: 18210302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.
    Borkamo ED; Fluge O; Mella O; Akslen LA; Bruland O; Dahl O
    Radiother Oncol; 2008 Mar; 86(3):435-42. PubMed ID: 18313158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
    Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
    Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
    Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
    Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.
    Simantov R; Febbraio M; Silverstein RL
    Matrix Biol; 2005 Feb; 24(1):27-34. PubMed ID: 15748999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
    Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
    Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined low-dose chemotherapy inhibiting angiogenesis and growth of Lewis lung cancinoma xenografts in mice].
    Qiu M; Yi C; Hou M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jul; 37(4):534-7. PubMed ID: 16909595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
    Ishida T; Shiraga E; Kiwada H
    J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.
    Quesada AJ; Nelius T; Yap R; Zaichuk TA; Alfranca A; Filleur S; Volpert OV; Redondo JM
    Cell Death Differ; 2005 Jun; 12(6):649-58. PubMed ID: 15818399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
    Balsari A; Tortoreto M; Besusso D; Petrangolini G; Sfondrini L; Maggi R; Ménard S; Pratesi G
    Eur J Cancer; 2004 May; 40(8):1275-81. PubMed ID: 15110894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shear stress modulates the expression of thrombospondin-1 and CD36 in endothelial cells in vitro and during shear stress-induced angiogenesis in vivo.
    Bongrazio M; Da Silva-Azevedo L; Bergmann EC; Baum O; Hinz B; Pries AR; Zakrzewicz A
    Int J Immunopathol Pharmacol; 2006; 19(1):35-48. PubMed ID: 16569344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.